HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-kappa;B pathways

Inflammation Research

Volumn 61, Issue 5, 2012, Pages 521-533

  Shimp III, Samuel K ^a   Parson, Carl D ^b   Regna, Nicole L ^a   Thomas, Alicia N ^a   Chafin, Cristen B ^a   Reilly, Christopher M ^c   Rylander, M Nichole ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b ELIZABETH CITY STATE UNIVERSITY   (United States)

^c EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

17 DMAG; Heat shock protein; Interleukin 6; Nitric oxide; Nuclear factor kappa; b

Indexed keywords

ALVESPIMYCIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; BENZOQUINONES; CELL LINE; CELL SURVIVAL; HSP90 HEAT-SHOCK PROTEINS; I-KAPPA B KINASE; INTERFERON-GAMMA; INTERLEUKIN-6; LACTAMS, MACROCYCLIC; LIPOPOLYSACCHARIDES; MICE; NF-KAPPA B; NITRIC OXIDE; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863099073     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0442-x     Document Type: Article

References (67)

1. Csermely P, Schnaider T, Soti C, Prohászka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications: a comprehensive review. Pharmacol Ther. 1998;79(2):129-68.
2. Blagg BS, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev. 2006;26(3):310-38.
3. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8(4):S55-S61.
4. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32(3):517-30.
5. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002;277(42):39858- 66.
6. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA. 2000;97(20): 10832-7.
7. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003;63(9):2139-44.
8. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761-72.
9. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228(2):111-33.
10. Shen G, Wang M, Welch TR, Blagg BS. Design, synthesis, and structure-activity relationships for chimeric inhibitors of Hsp90. J Org Chem. 2006;71(20):7618-31.
11. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006;12(22):6826-35.
12. Bucci M, Roviezzo F, Cicala C, Sessa WC, Cirino G. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br J Pharmacol. 2000;131(1):13-6.
13. Miao RQ, Fontana J, Fulton D, Lin MI, Harrison KD, Sessa WC. Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28(1):105-11.
14. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2002;277(12):10346-53.
15. Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol. 2009;144(3):358-66.
16. Egorin M, Lagattuta T, Hamburger D, Covey J, White K, Musser S, et al. Pharmacokinetics, tissue distribution, and metabolism of 17- (dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 2002;49(1):7-19. doi:10.1007/s00280- 001-0380-8.
17. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC707545) in C.B-17SCIDmice bearingMDA-MB- 231human breast cancer xenografts. CancerChemother Pharmacol. 2005;55(1):21-32. doi:10.1007/s00280-004-0865-3.
18. Holzbeierlein J, Windsperger A, Vielhauer G. Hsp90: a drug target? Curr Oncol Rep. 2010;12(2):95-101.
19. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010;116(1):45-53.
20. Wax S, Piecyk M, Maritim B, Anderson P. Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum. 2003;48(2):541-50.
21. Mandrekar P, Catalano D, Jeliazkova V, Kodys K. Alcohol exposure regulates heat shock transcription factor binding and heat shock proteins 70 and 90 in monocytes and macrophages: implication for TNF-a regulation. J Leukoc Biol. 2008;84(5): 1335-45.
22. Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G, Snead C, Cannon J, et al. Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med. 2007;176(7):667-75.
23. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, et al. Lipopolysaccharide- induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res. 2008;78(3):546-53.
24. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol. 2003;33(3):597-605.
25. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13(2):85-94.
26. Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak- STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol. 2007;82(2):237-43.
27. Maira SM, Finan P, Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol. 2010;347:209-39.
28. Shang L, Tomasi TB. The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J Biol Chem. 2006;281(4):1876-84.
29. Lin C-F, Tsai C-C, Huang W-C, Wang C-Y, Tseng H-C, Wang Y, et al. IFN-c synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10. J Cell Biochem. 2008;105(3):746-55.
30. Dalpke AH, Heeg K. Synergistic and antagonistic interactions between LPS and superantigens. J Endotoxin Res. 2003;9(1):51-4.
31. Takeishi Y, Kubota I. Role of toll-like receptor mediated signaling pathway in ischemic heart. Front Biosci. 2009;14:2553-8.
32. Babchia N, Calipel A, Mouriaux F, Faussat A-M, Mascarelli F. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WTB-Raf-expressing uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 2008;49(6): 2348-56.
33. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999;26(2):318-24.
34. Shen H-Y, He J-C, Wang Y, Huang Q-Y, Chen J-F. Geldanamycin induces heat shock protein 70 and protects against MPTPinduced dopaminergic neurotoxicity in mice. J Biol Chem. 2005;280(48):39962-9.
35. Zhang H, Chung D, Yang Y-C, Neely L, Tsurumoto S, Fan J, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther. 2006;5(5):1256-64.
36. Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145-51.
37. Marsh CB, Pomerantz RP, Parker JM, Winnard AV, Mazzaferri EL, Moldovan N, et al. Regulation of monocyte survival in vitro by deposited IgG: role of macrophage colony-stimulating factor. J Immunol. 1999;162(10):6217-25.
38. Ottonello L, Bertolotto M, Montecucco F, Dapino P, Dallegri F. Dexamethasone-induced apoptosis of human monocytes exposed to immune complexes. Intervention of CD95- and XIAP-dependent pathways. Int J Immunopathol Pharmacol. 2005;18(3):403-15.
39. Ayrault O, Godeny MD, Dillon C, Zindy F, Fitzgerald P, Roussel MF, et al. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci USA. 2009;106(40):17037-42.
40. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2007;11(1-2):32-50.
41. Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity. Immunol Res. 2005;31(1):47-55.
42. Wu T, Mohan C. The AKT axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets. 2009;9(2):145-50.
43. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-Kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappa B p65/RelA subunit. Mol Cell Biol. 1999;19(7):4798-805.
44. Weichhart T, Säemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis. 2008;67(SUPPL. 3):iii70-iii4.
45. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol. 2004;500(1-3):255-66.
46. Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for I[kappa]B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-[kappa]B activation. Oncogene. 2004;23(31):5378-86.
47. Mohan S, Konopinski R, Yan B, Centonze VE, Natarajan M. High glucose-induced IKK-Hsp-90 interaction contributes to endothelial dysfunction. Am J Physiol Cell Physiol. 2009;296(1):C182-C92.
48. Lee KH, Jang Y, Chung JH. Heat shock protein 90 regulates IkappaB kinase complex and NF-kappaB activation in angiotensin II-induced cardiac cell hypertrophy. Exp Mol Med. 2010;42(10):703-11.
49. Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer. 2010;10:481.
50. Madrigal-Matute J, Lopez-Franco O, Blanco-Colio LM, Munoz- Garcia B, Ramos-Mozo P, Ortega L, et al. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovasc Res. 2010;86(2):330-7.
51. Gomard T, Michaud HA, Tempe D, Thiolon K, Pelegrin M, Piechaczyk M. An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells. PLoS One. 2010;5(3):e9585.
52. Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life. 1999;48(4):429-33.
53. Chaudhury S, Welch TR, Blagg BSJ. Hsp90 as a target for drug development. ChemMedChem. 2006;1(12):1331-40.
54. Clark CB, Rane MJ, El Mehdi D, Miller CJ, Sachleben LR Jr, Gozal E. Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. Free Radic Biol Med. 2009;47(10):1440-9.
55. Ghoshal S, Rao I, Earp J, Jusko W, Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol. 2010;66(4):681-9.
56. Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol. 1997;17(9):5317-27.
57. Calderwood SK, Mambula SS, Gray PJ Jr, Theriault JR. Extracellular heat shock proteins in cell signaling. FEBS Lett. 2007;581(19):3689-94.
58. Pockley AG, Calderwood SK, Multhoff G. The atheroprotective properties of Hsp70: a role for Hsp70-endothelial interactions? Cell Stress Chaperones. 2009;14(6):545-53.
59. de Jong PR, Schadenberg AW, Jansen NJ, Prakken BJ. Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects. Cell Stress Chaperones. 2009;14(2):117-31.
60. Chen H, Wu Y, Zhang Y, Jin L, Luo L, Xue B, et al. Hsp70 inhibits lipopolysaccharide-induced NF-kappaB activation by interacting with TRAF6 and inhibiting its ubiquitination. FEBS Lett. 2006;580(13):3145-52.
61. Oates JC. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity. 2010;43(1):56-63.
62. Howard M, Roux J, Lee H, Miyazawa B, Lee J-W, Gartland B, et al. Activation of the stress protein response inhibits the STAT1 signalling pathway and iNOS function in alveolar macrophages: role of Hsp90 and Hsp70. Thorax. 2010;65(4):346-53.
63. Antonova G, Lichtenbeld H, Xia T, Chatterjee A, Dimitropoulou C, Catravas JD. Functional significance of hsp90 complexes with NOS and sGC in endothelial cells. Clin Hemorheol Microcirc. 2007;37(1-2):19-35.
64. Kiang JG, Smith JT, Agravante NG. Geldanamycin analog 17-DMAG inhibits iNOS and caspases in gamma-irradiated human T cells. Rad Res. 2009;172(3):321-30.
65. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(SUPPL. 2):S3.
66. Stephanou A, Isenberg DA, Akira S, Kishimoto T, Latchman DS. The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways cooperate to mediate the activation of the hsp90beta gene by interleukin-6 but have opposite effects on its inducibility by heat shock. Biochem J. 1998;330(Pt 1):189-95.
67. KH Tsui, TH Feng, WC Hsieh, PL Chang, HH Juang. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells. Acta Pharmacol Sin. 2008;29(11):1334-41.